Press Releases :: Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

May 13, 2024

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 7, 2024

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

May 1, 2024

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

Apr 25, 2024

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

Mar 21, 2024

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 18, 2024

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Mar 15, 2024

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

Mar 13, 2024

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

Mar 11, 2024

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Jan 5, 2024

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

rss_feed News RSS